KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Total Current Liabilities (2016 - 2026)

Amgen has reported Total Current Liabilities over the past 18 years, most recently at $25.0 billion for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 8.46% year-over-year to $25.0 billion; the TTM value through Mar 2026 reached $25.0 billion, up 8.46%, while the annual FY2025 figure was $25.5 billion, 10.35% up from the prior year.
  • Total Current Liabilities for Q1 2026 was $25.0 billion at Amgen, down from $25.5 billion in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $25.5 billion in Q4 2025 and troughed at $12.6 billion in Q2 2022.
  • A 5-year average of $19.0 billion and a median of $19.7 billion in 2024 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: fell 13.49% in 2022 and later surged 38.68% in 2024.
  • Year by year, Total Current Liabilities stood at $15.7 billion in 2022, then increased by 17.24% to $18.4 billion in 2023, then grew by 25.59% to $23.1 billion in 2024, then rose by 10.35% to $25.5 billion in 2025, then fell by 2.1% to $25.0 billion in 2026.
  • Business Quant data shows Total Current Liabilities for AMGN at $25.0 billion in Q1 2026, $25.5 billion in Q4 2025, and $21.8 billion in Q3 2025.